https://orcid.org/0000-0003-3656-4353
References
- Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372–401. doi:10.3322/caac.21728
- Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685. doi:10.1001/jama.2021.0106
- Kawai S, Takeshima N, Hayasaka Y, et al. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. BMC Cancer. 2021;21(1):116. doi:10.1186/s12885-021-07823-7
- Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–177. doi:10.1038/s41571-022-00719-w
- Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21(7):529–540. doi:10.1038/s41573-022-00493-5
- Butterfield LH, Kaufman HL, Marincola FM. Cancer Immunotherapy Principles and Practice. Springer Publishing Company; 2021.
- Ghazvinian Z, Abdolahi S, Ahmadvand M, et al. Chemo-immune cell therapy by intratumoral injection of adoptive NK cells with capecitabine in gastric cancer xenograft model. BioImpacts. 2023;13(5):383–392. doi:10.34172/bi.2022.26386
- Peereboom DM, Alban TJ, Grabowski MM, et al. Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. 2019;4(22):e130748. doi:10.1172/jci.insight.130748
- Zhang J, Zhang Q, Liu Z, et al. Efficacy and safety of recombinant human adenovirus type 5 (H101) in persistent, recurrent, or metastatic gynecologic malignancies: a retrospective study. Front Oncol. 2022;12:877155. doi:10.3389/fonc.2022.877155
- Zhang Q, Zhang J, Liu Z, et al. Recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with persistent, recurrent, or metastatic cervical cancer: genomic profiling relating to clinical efficacy. Drug Des Devel Ther. 2023;17:3507–3522. doi:10.2147/dddt.S429180
- Zhang R, Cui Y, Guan X, Jiang X. A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study. Front Oncol. 2021;11:752504. doi:10.3389/fonc.2021.752504
- Huang L, Zhao H, Shan M, et al. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. Cancer Med. 2022;11(23):4575–4587. doi:10.1002/cam4.4845
- Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol. 2003;21(11):1328–1335. doi:10.1038/nbt887
- Derakhshani A, Hashemzadeh S, Asadzadeh Z, et al. Cytotoxic T-Lymphocyte Antigen-4 in colorectal cancer: another therapeutic side of capecitabine. Cancers (Basel). 2021;13(10):2414. doi:10.3390/cancers13102414
- Wang B, Zhong C, Liao Z, et al. Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: a multicenter, observational, real-world study. Thorac Cancer. 2023;14(30):3051–3057. doi:10.1111/1759-7714.15101
- Niu CG, Zhang J, Rao AV, Joshi U, Okolo P. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status. World J Clin Oncol. 2024;15(4):540–547. doi:10.5306/wjco.v15.i4.540
- Wang L, Zhang T, Zheng Y, et al. Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cgas/sting pathway for colorectal cancer. Mater Today Bio. 2023;23:100809. doi:10.1016/j.mtbio.2023.100809